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Introduction
H
epatitis  B  virus  (HBV)  affects  more  than 
2  billion  individuals  worldwide,  and 
approximately  350  million  people  are  long-term 
HBV  carriers  (1). Turkey  has  medium  endemicity 
for incidence of HBV infection, and the estimated 
number  of  HBV  carriers  is  2.4-6  million  people 
(2). Chronic hepatitis B (CHB) is induced by the 
chronic replication of HBV in the liver and has a 
poor prognosis, with 20–40% of infected individuals 
developing  liver  cirrhosis,  noncompensated  liver 
disorder, or hepatocellular carcinoma (HCC) (3).
Studies on hepatitis B seroprevalence were done 
in different regions of Turkey. Kangin et al. carried 
out a large-scale study in endemic regions and found 
that  the  seroprevalence  was  8.1%  among  10,391 
children (4). In northern Turkey, the seroprevalence 
of hepatitis B among pregnant women was found 
to be 2.1% (5). As is well-known, hepatitis B is very 
prominent  among  blood  donors,  and  the  general 
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Background and Aims: In the present study, we aimed to present the initial results of chronic hepatitis B patients who 
received entecavir (ETV) therapy in our hospital in Izmir, Turkey. 
Methods: A total of 52 patients were enrolled in the study. ETV was given in a dosage of 0.5 mg/day and 1 mg/day to 50 
patients without Lamivudine/Adefovir (LAM/ADV) resistance and to 2 patients with LAM resistance, respectively. ETV 
was given in a dose of 0.5mg/day every three days to one patient with a renal transplant. The treatment duration was 
48 weeks.
Results: Out of a total of 52 patients, 23 (44.23%) were hepatitis B e antigen (HBeAg)-positive, and 29 (55.77%) of 
them were HBeAg-negative. In 29 HBeAg-negative patients, early biochemical and virological responses were 82.6% 
and 100%, respectively. These responses were 97% and 79.3% in the 12th month. In HBeAg-positive patients, early 
biochemical and virological responses were found to be 78.3% and 82.6%, respectively. They were 100% and 52.2% in 
the 12th month. HBeAg seroconversion developed in 4.5% of HBeAg-positive patients.
Conclusions: According to our one-year ETV treatment results, both HBeAg-negative and -positive patients had high 
biochemical and virological response rates. Their HBeAg seroconversion rate was 4.5%. In conclusion, more studies of 
longer duration are needed to understand the required duration of treatment, to assess its long-term effectiveness, and to 
check the resistance and side effects of ETV. There is also a need to have late-phase results after treatment.
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seroprevalence  ratio  was  found  to  be  4.19%  in  a 
previous study carried out by Emekdas et al. (6).
Treatment  of  CHB  is  aimed  at  the  sustained 
inhibition of HBV replication and at the remission 
of liver disease (7), ultimately preventing progression 
to liver cirrhosis or HCC (8). For its treatment, agents 
like interferon alpha (IFN-α), pegylated interferons 
(PEG-IFN),  lamivudine  (LAM),  adefovir  (ADV), 
entecavir  (ETV)  and  tenofovir  (TDF)  have  been 
used in many countries, as well as in Turkey. 
The  antiviral  agents  ETV  and  TDF  were 
introduced to Turkey in 2007 and 2008, respectively. 
ETV  is  a  strong  and  selective  inhibitor  of  HBV 
DNA polymerase. Previous studies have shown that 
its reliability and its side-effect profile are similar to 
that of LAM. In our study, we assessed the short- 
and long-term effects of ETV on chronic hepatitis 
B patients receiving ETV treatment, and they are 
followed at three-month intervals. 
Materials and Methods
Routinely,  the  naïve  or  previously  treated 
hepatitis  B  patients  have  been  followed  in  our 
outpatient clinic and their alanine aminotransferase/
aspartate  aminotransferase  (AST/ALT),  hepatitis 
B  surface  antigen  (HBsAg),  antibody  to  hepatitis 
B surface antigen (anti-HBs), hepatitis B e antigen 
(HBeAg), antibodies to hepatits B e antigen (anti-
HBe), hepatitis B virus DNA (HBV-DNA)levels are 
checked at three-month intervals (in the 3rd, 6th , 
9th and 12th month). Additionally, LAM- and ADV-
resistance tests were applied to all individual subjects. 
When the subjects first began to be followed, liver 
biopsies were done on them. 
The following criteria were used for enrolling the 
patients in the study: elevated levels in liver function 
tests, elevated levels of HBV DNA (> 105 copy/ml 
in HBeAg positive patients, >104 copy/ml in HBe 
negative patients), and histology activity index (HAI) 
score of ≥4 and fibrosis ≥2 in both groups.
Patients  having  HIV  infections  were  excluded 
from the study because of the contraindications. 
A total of 52 patients were enrolled in the study. A 
dose of 0.5 mg/day and 1 mg/day of ETV was given 
to 50 patients without LAM/ADV resistance and to 
2  patients  with  LAM  resistance,  respectively. The 
drug was administered in a dose of 0.5mg/day, every 
three days, to one patient with a renal transplant. 
The treatment duration was 48 weeks.
The  resistance  against  LAM  and  ADV  was 
evaluated  using  the  multiplex  PCR  and  reverse 
hybridization  tools  (INNO-LIPA  HBV  DR  v2, 
Innogenetics, Belgium). According to the criteria of 
the Turkish Association for the Study of the Liver, 
an ALT/AST normalization in the 3rd, 6th and 12th 
month is accepted as a biochemical response (BR) 
in chronic hepatitis B patients, and 2 logarithmic 
decreases in the HBV DNA level in the 3rd month, 
lower than 104 copy/ml in the 6th month and an 
undetectable level in the 12th month are accepted 
as a virological response (VR). In HBeAg-positive 
patients,  the  detection  of  anti-HBe  antibodies  is 
accepted as a serological response (SR).
Results
Nineteen (36.6%) and 33 (63.4%) of the patients 
were  female  and  male,  respectively.  Their  mean 
age was 37.9 (between 17 and 67) years. Thirty-
eight (73.1%) of the patients were naïve, while 14 
(26.9%) patients had previous nucleos(t)ide analogue 
treatment (with LAM and/or ADV). LAM and ADV 
resistance were detected in two patients.
Out of 52 patients, 23 (44.2%) were HBeAg-
positive,  while  29  (55.8%)  were  HBeAg-negative. 
ETV  treatment  results  and  the  patients’  details 
are  provided  in  Table  1  and  Table  2.  HBeAg 
seroconversion developed in 4.5% of the HBeAg-
positive patients.
The analyses showed that there is no significant 
relationship between the previous nucleoside use and 
the virological response; between the level of baseline 
HBV DNA and virological response; between the 
beginning  level  of  fibrosis  value  and  virological 
response in any of the groups (data not shown).
Discussion
In the present study, the results of the 48-week 
analysis of this study population of 38 nucleoside-
naïve  and  14  non-naïve  Turkish  patients  with 
chronic hepatitis B were presented. A resurgence of 
viral replication after the specific treatment, and drug 
resistance, are two common problems in the antiviral 
therapy  of  CHB  patients.  Previous  studies  have 
shown that ETV has a high genetic barrier, with a 
low incidence of resistance, in nucleoside-naïve CHB 
patients. The  cumulative  probability  of  genotypic 
resistance to ETV remains low, at the ratio of 1.2% 
after 6 years of therapy, for nucleoside-naïve patients 
(9). Other nucleoside or nucleotide analogues such as 
LAM or ADV have higher reported rates of resistance 
– up to 65% with LAM and 29% with ADV within 
5 years (7, 10). In chronic hepatitis B patients with 
LAM resistance, the virological response was found 
to be 59.6% after ADV treatment (11). Hepatitis Monthly, Summer 2010; 10(3): 183-187
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al. (15) compared ETV and LAM treatment of naïve 
HBeAg-positive CHB patients and after the first year 
of the study, the virological response was found to be 
67% in the ETV group and 36% in the LAM group. 
Biochemical response rates were 68% and 60% in 
the ETV and LAM groups, respectively. Lai et al. 
compared ETV and LAM treatment of naïve HBeAg-
negative CHB patients; they have found virological 
responses of 90% and 72% in the ETV and LAM 
groups, respectively. The biochemical response of the 
ETV group was found to be 78% while that of the 
LAM group was found to be 71% (16). 
In  our  study,  after  a  48-week  treatment  with 
ETV,  the  virological  and  biochemical  response 
rates of naïve CHB patients were higher in HBeAg-
negative  patients  (79.3%  and  97.0%)  than  in 
HBeAg-positive patients (52.2% and 100%). The 
virological response rates of naïve HBeAg-negative 
patients (80%) and HBeAg-positive CHB patients 
(55.6%) were found to be lower than in the other 
studies; however, the biochemical response rates in 
both groups (100% in HBeAg-positive naïve CHB 
patients, and 95% in HBeAg-negative naïve CHB 
patients, at year one of ETV therapy) were found 
to be higher when compared to the results of other 
studies. The reason for these differences is doubtless 
due to the smaller number of patients studied. We 
need to observe a large number of CHB patients over 
a longer period. A total of 14 patients (5 HBeAg-
positive, 9 HBeAg-negative) had previous treatment 
with other nucleoside analogues. Both the virological 
and the biochemical response rates of these patients 
in the first year of ETV therapy were found to be 
higher  than  the  ones  mentioned  in  other  studies 
(Table 2).
Studies  have  shown  that  in  LAM-resistant 
CHB patients, response rates to ETV over a long-
term treatment period should decrease, because of 
the probability of cross resistance between the two 
drugs. In the study carried out by Hadziyannis et 
al. (10), virological response rates to ETV in naïve 
CHB patients at year three were 94%, whereas these 
response rates for the LAM-resistant group were 40%. 
In the same study, naïve patients who had received 
three years of ETV treatment had <1% resistance; 
however the resistance rate became 30% after three 
years of ETV treatment, in the LAM-resistant group. 
Nagasaki et al. (17) have reported that in 3 out of 4 
LAM-resistant subjects, resistance developed in the 
period from the 52nd to the 130th week. In the study 
conducted by Tilmann (18) in Germany, 9% of the 
subjects with LAM resistance developed resistance 
after  2  years.  In  a  multi-centered  study  involving 
many LAM-resistant HBeAg-positive CHB patients, 
the  group  that  continued  LAM  treatment  for  52 
weeks had a 4% virological and biochemical response 
(6/145), but this rate was 55% in the group which 
was treated with 1 mg/day of ETV. A total of 10 out of 
141 patients showed genotypical ETV resistance and 
2 had virological rebound. In our study, 2 patients 
who  had  genotypical  LAM  resistance  at  baseline 
responded to 1 year of ETV treatment, however no 
genotypical resistance tests were conducted in the 
present study. 
In Turkey, it is reported that multidrug resistance 
against ADV and ETV was also detected in LAM-
resistant  hepatitis  B  patients  who  received  LAM 
therapy for one year (19). 
It is reported that extended therapy with ETV 
over  5  years  maintained  or  increased  rates  of 
HBV  DNA  suppression  and  ALT  normalization. 
Additional  patients  also  achieved  HBeAg  loss 
and  seroconversion.  ETV  provides  sustained  viral 
suppression  with  minimal  resistance  during  long-
term  treatment  of  HBeAg-positive  CHB  (20).  In 
our study, after one year of treatment with ETV, the 
response rates of HBeAg-negative patients were found 
to be elevated. HBeAg-positive patients’ virological 
and biochemical response rates were also found to be 
high at the end of the first year, although the HBeAg 
seroconversion  rate  was  4.5%.  In  conclusion,  we 
need to observe more patients for a longer period of 
time, in order to assess the long-term effectiveness, 
safety and resistance profile of ETV.
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